Lapatinib
FDA Approved: * September 29, 2020Pharm Company: * NATCO PHARMA LTD
Category: Cancer
Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb marketed by Novartis) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer ... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.